Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852966 | 0.87 | NAAA (0.43) | EPHX1NAAAHTR2CHCAR2FAAH | |
| SCHEMBL28914773 | 0.86 | ALDH1A1 (0.39) | HTR2CHCAR2TSHRALDH1A1FDPS | |
| SCHEMBL28914772 | 0.86 | ALDH1A1 (0.39) | HTR2CHCAR2TSHRALDH1A1FDPS | |
| Acetic Acid SCHEMBL11697268 | 0.83 | ALDH1A1 (0.41) | HTR2CHCAR2TSHRALDH1A1FDPS | |
| Acetic Acid SCHEMBL11697282 | 0.83 | ALDH1A1 (0.41) | HTR2CHCAR2TSHRALDH1A1FDPS | |
| SCHEMBL8754911 | 0.82 | NAAA (0.46) | EPHX1NAAAHTR2CHCAR2FAAH | |
| SCHEMBL8755187 | 0.82 | NAAA (0.46) | EPHX1NAAAHTR2CHCAR2FAAH | |
| SCHEMBL5204094 | 0.81 | ALDH1A1 (0.44) | EPHX1NAAAHTR2CHCAR2ACHE | |
| SCHEMBL27530078 | 0.81 | ACHE (0.41) | HCAR2ACHETSHRALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL7377198 | 0.80 | ALDH1A1 (0.42) | EPHX1NAAAHTR2CHCAR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030214-B2 | Ureins derived from α, ω, diamino acids and process for their preparation | SOLVAY (SOCIETE ANONYME) (BE) | 2006-04-18 | — | — | US | disclosed |
| US-20020058784-A1 | Ureins derived from alpha, omega, -diamond acids and process for their preparation | CALLENS ROLAND (BE) | 2002-05-16 | — | — | US | disclosed |
| US-6310178-B1 | AS THE N-TERMINAL RESIDUE OF BIOLOGICALLY ACTIVE PEPTIDES, E.G, THYROTROPIN RELEASING HORMONE (BY REPLACING THE N-TERMINAL PYROGLUTAMYL GROUP); IMPARTING INCREASED RESISTANCE TO PROTEOLYTIC DIGESTION | SOLVAY, S.A. (BE) | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058784-A1 | Ureins derived from alpha, omega, -diamond acids and process for their preparation | UPP1, URB2, UFM1 | EPHX1 1259/4885NAAA 565/4885HTR2C 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.